Xueli Ji , Chao Li , Jinyu Gou , Xiaodong Wu , Yafu Yin , Hongliang Fu , Hui Wang , Suyun Chen
{"title":"18F-FDG PET/CT in pediatric langerhans cell histiocytosis: relation to BRAFv600e mutation and risk stratification","authors":"Xueli Ji , Chao Li , Jinyu Gou , Xiaodong Wu , Yafu Yin , Hongliang Fu , Hui Wang , Suyun Chen","doi":"10.1016/j.ejrad.2025.112361","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>BRAF<sup>V600E</sup> correlates with high-risk features and poor response to chemotherapy in pediatric Langerhans cell histiocytosis (LCH). This study aimed to evaluate the role of <sup>18</sup>F-FDG PET/CT in risk stratification and to explore the relationship between <sup>18</sup>F-FDG uptake and BRAF<sup>V600E</sup> mutation in LCH.</div></div><div><h3>Methods</h3><div>Pretreatment <sup>18</sup>F-FDG PET/CT scans from 114 newly diagnosed pediatric LCH were retrospectively analyzed. The associations between imaging findings and clinico-pathological parameters were investigated.</div></div><div><h3>Results</h3><div>PET/CT imaging led to a change of disease stratification in 47 (41.2 %) patients. The most common additional organs detected by PET/CT were lymph nodes and thymus. Elevated C-reactive protein (CRP) levels were associated with upstaging [Odds ratio (OR): 2.737, 95 % confidence interval (CI): 1.193–6.276, <em>p</em> = 0.017]. LCH lesions showed significantly higher SUVmax in patients with elevated CRP levels compared to those with normal levels (10.2 ± 4.7 vs. 7.3 ± 3.6, <em>p</em> = 0.001). BRAF<sup>V600E</sup> status was tested in 70 patients. Lower <sup>18</sup>F-FDG uptake (SUVmax: 8.2 ± 3.3 vs. 10.8 ± 4.9, <em>p</em> = 0.019) was observed in mutated-BRAF<sup>V600E</sup>. Multivariate logistic regression analysis revealed that SUVmax ≤ 10.6 (OR: 6.868, 95 % CI: 1.751–26.946, <em>p</em> = 0.006), absence of thymus involvement (OR: 11.849, 95 %CI: 1.907–73.635, <em>p</em> = 0.008) and CRP ≥ 15.0 mg/L (OR: 8.062, 95 % CI: 1.538–42.263, <em>p</em> = 0.014) significantly correlated with BRAF<sup>V600E</sup> mutation.</div></div><div><h3>Conclusions</h3><div>PET/CT identifies extra-osseous diseases in about 40% of patients, especially those with elevated CRP levels. Moreover, <sup>18</sup>F-FDG PET/CT findings were significantly associated with BRAF<sup>V600E</sup> mutation status, although wide CIs warrant cautious interpretation.</div></div>","PeriodicalId":12063,"journal":{"name":"European Journal of Radiology","volume":"191 ","pages":"Article 112361"},"PeriodicalIF":3.3000,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Radiology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0720048X25004474","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0
Abstract
Objective
BRAFV600E correlates with high-risk features and poor response to chemotherapy in pediatric Langerhans cell histiocytosis (LCH). This study aimed to evaluate the role of 18F-FDG PET/CT in risk stratification and to explore the relationship between 18F-FDG uptake and BRAFV600E mutation in LCH.
Methods
Pretreatment 18F-FDG PET/CT scans from 114 newly diagnosed pediatric LCH were retrospectively analyzed. The associations between imaging findings and clinico-pathological parameters were investigated.
Results
PET/CT imaging led to a change of disease stratification in 47 (41.2 %) patients. The most common additional organs detected by PET/CT were lymph nodes and thymus. Elevated C-reactive protein (CRP) levels were associated with upstaging [Odds ratio (OR): 2.737, 95 % confidence interval (CI): 1.193–6.276, p = 0.017]. LCH lesions showed significantly higher SUVmax in patients with elevated CRP levels compared to those with normal levels (10.2 ± 4.7 vs. 7.3 ± 3.6, p = 0.001). BRAFV600E status was tested in 70 patients. Lower 18F-FDG uptake (SUVmax: 8.2 ± 3.3 vs. 10.8 ± 4.9, p = 0.019) was observed in mutated-BRAFV600E. Multivariate logistic regression analysis revealed that SUVmax ≤ 10.6 (OR: 6.868, 95 % CI: 1.751–26.946, p = 0.006), absence of thymus involvement (OR: 11.849, 95 %CI: 1.907–73.635, p = 0.008) and CRP ≥ 15.0 mg/L (OR: 8.062, 95 % CI: 1.538–42.263, p = 0.014) significantly correlated with BRAFV600E mutation.
Conclusions
PET/CT identifies extra-osseous diseases in about 40% of patients, especially those with elevated CRP levels. Moreover, 18F-FDG PET/CT findings were significantly associated with BRAFV600E mutation status, although wide CIs warrant cautious interpretation.
期刊介绍:
European Journal of Radiology is an international journal which aims to communicate to its readers, state-of-the-art information on imaging developments in the form of high quality original research articles and timely reviews on current developments in the field.
Its audience includes clinicians at all levels of training including radiology trainees, newly qualified imaging specialists and the experienced radiologist. Its aim is to inform efficient, appropriate and evidence-based imaging practice to the benefit of patients worldwide.